Simon Oesterreich1, Monika Lindemann2, David Goldblatt3, Peter A Horn4, Benjamin Wilde5, Oliver Witzke6. 1. Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 2. Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Electronic address: monika.lindemann@uk-essen.de. 3. University College London, Institute of Child Health, London, United Kingdom; World Health Organisation, Pneumococcal Serology Reference Laboratory, London, United Kingdom. 4. Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 5. Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. 6. Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND: Vaccination against S. pneumoniae is recommended by national guidelines. Moderate immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) has been reported in adult kidney transplant recipients (KTR). This study further defines the immunogenicity of PCV13 in this cohort. METHODS: 49 KTR were immunized with PCV13. A validated opsonophagocytic killing assay (OPA), a global anti-pneumococcal capsular polysaccharide (anti-PCP) IgG, IgG2, IgM and IgA ELISA, and - for selected patients - a serotype specific anti-PCP WHO reference ELISA were performed pre-vaccination and at month 1 and 12 post-vaccination. RESULTS: Geometric mean OPA titers increased significantly for 13/13 serotypes at month 1 and for 10/13 serotypes at month 12 post-vaccination. Vaccine response defined as an OPA titer ≥1:8 was reached in 9/13 serotypes (median). 53% reached the vaccine response criteria at month 1 and 45% at month 12. At month 1 after vaccination, the median OPA titer in an age-group matched healthy reference population was 5- to 10-fold higher than in KTR. OPA titers correlated strongly with results to the global and serotype specific anti-PCP IgG ELISA. Lower OPA titers significantly (p < 0.05) correlated with albuminuria, an interval between vaccination and transplantation <12 months, age and treatment with mycophenolate mofetil. Global IgG, IgG2, IgM and IgA, as well as serotype specific anti-PCP antibody concentrations (12/13 serotypes) increased significantly at month 1 and 12 post-vaccination. CONCLUSIONS: Kidney transplant recipients show a significant humoral response after vaccination with PCV13. Functional antibody response exists, but is not as vigorous as in healthy adults.
BACKGROUND: Vaccination against S. pneumoniae is recommended by national guidelines. Moderate immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) has been reported in adult kidney transplant recipients (KTR). This study further defines the immunogenicity of PCV13 in this cohort. METHODS: 49 KTR were immunized with PCV13. A validated opsonophagocytic killing assay (OPA), a global anti-pneumococcal capsular polysaccharide (anti-PCP) IgG, IgG2, IgM and IgA ELISA, and - for selected patients - a serotype specific anti-PCP WHO reference ELISA were performed pre-vaccination and at month 1 and 12 post-vaccination. RESULTS: Geometric mean OPA titers increased significantly for 13/13 serotypes at month 1 and for 10/13 serotypes at month 12 post-vaccination. Vaccine response defined as an OPA titer ≥1:8 was reached in 9/13 serotypes (median). 53% reached the vaccine response criteria at month 1 and 45% at month 12. At month 1 after vaccination, the median OPA titer in an age-group matched healthy reference population was 5- to 10-fold higher than in KTR. OPA titers correlated strongly with results to the global and serotype specific anti-PCP IgG ELISA. Lower OPA titers significantly (p < 0.05) correlated with albuminuria, an interval between vaccination and transplantation <12 months, age and treatment with mycophenolate mofetil. Global IgG, IgG2, IgM and IgA, as well as serotype specific anti-PCP antibody concentrations (12/13 serotypes) increased significantly at month 1 and 12 post-vaccination. CONCLUSIONS: Kidney transplant recipients show a significant humoral response after vaccination with PCV13. Functional antibody response exists, but is not as vigorous as in healthy adults.
Authors: Rachael F Kermond; Justyna E Ozimek-Kulik; Siah Kim; Stephen I Alexander; Deirdre Hahn; Alison Kesson; Nicholas Wood; Hugh J McCarthy; Anne M Durkan Journal: Pediatr Nephrol Date: 2022-07-14 Impact factor: 3.651
Authors: Marie-Luise Arnold; Falko M Heinemann; Simon Oesterreich; Benjamin Wilde; Anja Gäckler; David Goldblatt; Bernd M Spriewald; Peter A Horn; Oliver Witzke; Monika Lindemann Journal: Vaccines (Basel) Date: 2022-05-05
Authors: Reinhart Speeckaert; Jo Lambert; Luis Puig; Marijn Speeckaert; Hilde Lapeere; Sofie De Schepper; Nanja van Geel Journal: Drugs R D Date: 2021-06-09
Authors: Marta Garrido-Jareño; Leonor Puchades-Carrasco; Leticia Orti-Pérez; José Miguel Sahuquillo-Arce; María Del Carmen Meyer-García; Joan Mollar-Maseres; Carmina Lloret-Sos; Ana Gil-Brusola; José Luis López-Hontangas; José Manuel Beltrán-Garrido; Javier Pemán-García; Antonio Pineda-Lucena Journal: Sci Rep Date: 2021-03-22 Impact factor: 4.379
Authors: Anja Gäckler; Nils Mülling; Kim Völk; Benjamin Wilde; Ute Eisenberger; Hana Rohn; Peter A Horn; Oliver Witzke; Monika Lindemann Journal: Vaccines (Basel) Date: 2021-12-06